Apria: 'Dedicated focus' on home infusion
By HME News Staff
Updated Tue May 1, 2012
LAKE FOREST, Calif. - Apria Healthcare Group this week reported net revenues of $595.7 million for the three months ended March 31, 2012, compared to $536.7 million for the same period last year, an 11% increase.
It reported a net loss of $19.6 million vs. $21 million.
Revenues increased primarily due to boosts in volume in the home infusion therapy segment and the home respiratory therapy and home medical equipment segment, as well as the acquisition of Praxair assets in March 2011, according to a press release.
Apria reiterated its decision to create separate segments for home infusion therapy and home respiratory therapy/home medical equipment. In March, it named Daniel Greenleaf CEO of Coram, the principal operating subsidiary of the home infusion therapy segment; and Daniel Starck as CEO of Apria Healthcare, the principal operating subsidiary of the home respiratory therapy/home medical equipment segment.
“These structural changes give the company dedicated focus on its home infusion therapy business, while also providing specific leadership to the home respiratory therapy/home medical equipment business,” the company stated in the release.
Comments